SCHEMBL20021999

SCHEMBL20021999

CCC(C)NS(=O)(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.63
MMP9 P14780 6/20 0.63
ADAMTS4 O75173 4/20 0.63
MMP3 P08254 2/20 0.63
MMP13 P45452 2/20 0.63
MMP1 P03956 1/20 0.63
MMP7 P09237 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.61
NR3C1 P04150 1/20 0.56
ALDH1A1 P00352 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
CA14 Q9ULX7 1/20 0.54
SLC1A3 P43003 1/20 0.54
SLC1A2 P43004 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971671 0.90 SMN1; SMN2 (0.74) MMP2MMP9ADAMTS4MMP3MMP13
SCHEMBL6326385 0.85 ADAMTS4 (0.65) MMP2MMP9ADAMTS4MMP3MMP13
SCHEMBL6326378 0.85 ADAMTS4 (0.65) MMP2MMP9ADAMTS4MMP3MMP13
SCHEMBL18649869 0.84 MMP2 (0.67) MMP2MMP9ADAMTS4MMP3MMP13
SCHEMBL6613031 0.82 ADAMTS4 (0.70) MMP2MMP9ADAMTS4MMP3MMP13
SCHEMBL30444747 0.82 SMN1; SMN2 (0.64) MMP2MMP9ADAMTS4MMP3MMP13
SCHEMBL13889012 0.81 ALDH1A1 (0.83) MMP2MMP9ADAMTS4MMP3MMP13
SCHEMBL12169286 0.81 CA2 (0.75) MMP2MMP9MMP3MMP13MMP1
SCHEMBL16197361 0.80 TDP1 (0.55) SMN1; SMN2ALDH1A1CA12CA2CA9
SCHEMBL18457148 0.79 MMP2 (0.55) MMP2MMP9MMP3MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180093960-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2018-04-05 US disclosed
US-20180093960-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093960-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND LDLR, APOB, NR1H2 MMP2 2197/4885MMP9 3257/4885ADAMTS4 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.